Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc A Pfeffer

Showing results (361-370 of 520) with videos related to

Pageof 52
Sort By:
European Stroke Journal|April 23, 2019
Effect of single and dual renin-angiotensin blockade on stroke in patients with and without diabetes in VALIANTAzmil H Abdul-Rahim, Kieran F Docherty, Hicham Skali, et al.
Circulation|June 22, 2005
Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarctionScott D Solomon, Hicham Skali, Nagesh S Anavekar, et al.
JACC. Heart Failure|November 30, 2019
Influence of Age on Efficacy and Safety of Spironolactone in Heart FailureOrly Vardeny, Brian Claggett, Muthiah Vaduganathan, et al.
Circulation|November 23, 2011
Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experienceHicham Skali, Hans-Henrik Parving, Patrick S Parfrey, et al.
Circulation. Heart Failure|December 21, 2018
Cardiac Troponin I and Risk of Cardiac Events in Patients With Heart Failure and Preserved Ejection FractionPeder L Myhre, Eileen O'Meara, Brian L Claggett, et al.
The New England Journal of Medicine|March 12, 2013
Treatment of anemia with darbepoetin alfa in systolic heart failureKarl Swedberg, James B Young, Inder S Anand, et al.
European Journal of Heart Failure|March 2, 2026
Heart rate and atrial fibrillation/flutter in HFmrEF/HFpEF: a participant-level analysis across five randomized clinical trialsAlberto Foà, Henri Lu, Muthiah Vaduganathan, et al.
JACC. Heart Failure|October 4, 2024
Natriuretic Peptides, Kidney Function, and Clinical Outcomes in Heart Failure With Preserved Ejection FractionBrendon L Neuen, Muthiah Vaduganathan, Brian L Claggett, et al.
International Journal of Cardiology|February 4, 2023
Spironolactone effect on circulating procollagen type I carboxy-terminal propeptide: Pooled analysis of three randomized trialsJoão Pedro Ferreira, John G Cleland, Nicolas Girerd, et al.
JAMA Cardiology|August 25, 2018
Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical TrialPeder Langeland Myhre, Muthiah Vaduganathan, Brian L Claggett, et al.
Pageof 52

Showing results (361-370 of 520) with videos related to

Sort By:
Pageof 52
European Stroke Journal|April 23, 2019
Effect of single and dual renin-angiotensin blockade on stroke in patients with and without diabetes in VALIANTAzmil H Abdul-Rahim, Kieran F Docherty, Hicham Skali, et al.
Circulation|June 22, 2005
Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarctionScott D Solomon, Hicham Skali, Nagesh S Anavekar, et al.
JACC. Heart Failure|November 30, 2019
Influence of Age on Efficacy and Safety of Spironolactone in Heart FailureOrly Vardeny, Brian Claggett, Muthiah Vaduganathan, et al.
Circulation|November 23, 2011
Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experienceHicham Skali, Hans-Henrik Parving, Patrick S Parfrey, et al.
Circulation. Heart Failure|December 21, 2018
Cardiac Troponin I and Risk of Cardiac Events in Patients With Heart Failure and Preserved Ejection FractionPeder L Myhre, Eileen O'Meara, Brian L Claggett, et al.
The New England Journal of Medicine|March 12, 2013
Treatment of anemia with darbepoetin alfa in systolic heart failureKarl Swedberg, James B Young, Inder S Anand, et al.
European Journal of Heart Failure|March 2, 2026
Heart rate and atrial fibrillation/flutter in HFmrEF/HFpEF: a participant-level analysis across five randomized clinical trialsAlberto Foà, Henri Lu, Muthiah Vaduganathan, et al.
JACC. Heart Failure|October 4, 2024
Natriuretic Peptides, Kidney Function, and Clinical Outcomes in Heart Failure With Preserved Ejection FractionBrendon L Neuen, Muthiah Vaduganathan, Brian L Claggett, et al.
International Journal of Cardiology|February 4, 2023
Spironolactone effect on circulating procollagen type I carboxy-terminal propeptide: Pooled analysis of three randomized trialsJoão Pedro Ferreira, John G Cleland, Nicolas Girerd, et al.
JAMA Cardiology|August 25, 2018
Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical TrialPeder Langeland Myhre, Muthiah Vaduganathan, Brian L Claggett, et al.
Pageof 52